Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule belonging to the class of 2-benzylamino-s-triazines and pyrazolo[1,5-a][1,3,5]triazines. It has not been approved for any indication and is not currently in clinical trials beyond preclinical or early research phases. The primary known mechanism of action is inhibition of cyclin-dependent kinase 2 (CDK2), a serine/threonine protein kinase involved in cell cycle regulation. CDK inhibitors are being explored as potential anticancer agents due to their ability to block cell proliferation by interfering with key checkpoints in the cell cycle.[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol.